RxDoctor Payments Data

Judith Csanky, MD

Gastroenterology · Twin Falls, IDNPI 1598843039

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (55.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 64.9% of it on its own, with 10 other manufacturers making up the rest. 2023 is the largest year on record at $1,580, 4.9 times the $321 reported in 2019.

$2,434in general payments, 2019–2025

Across 30 payments — averaging $81.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Capsopro Services LLC$500
  • AbbVie$164
  • Takeda Pharmaceuticals U.S.A., Inc.$41
  • Pfizer$35
  • Intercept Pharmaceuticals, Inc.$31
  • plus $83 from 5 others

What the payments were for

  • Consulting fees$50021%
  • Travel & lodging$1,35656%
  • Food & beverage$57824%

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,434 in reported general payments places this provider in the 65th percentile of 70 gastroenterology providers in Idaho.

See all gastroenterology providers in Idaho

Medicare billing

Part B allowed, 2024
$17,577
Medicare patients
67
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase25$35,362
LinzessLinaclotide24$12,595
Mesalamine23$8,773
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates25$1,638
Pantoprazole Sodium149$1,619
Lubiprostone21$1,198
Ondansetron OdtOndansetron30$355
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl20$325
Lactulose12$292
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl18$268
Dicyclomine Hcl15$170
Promethazine Hcl14$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$164$12,59524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 70 gastroenterology providers in Idaho.

Other gastroenterology in Twin Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →